Reshaping Cultural Policies

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering

Retrieved on: 
Friday, September 29, 2023
Weight loss, Park Avenue, SEC filing, Sale, Register, Prospectus, Reshaping Cultural Policies, Form, Registration statement, Security (finance)

Each unit is being sold at a public offering price of $0.33.

Key Points: 
  • Each unit is being sold at a public offering price of $0.33.
  • Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.0 million.
  • The offering is expected to close on October 3, 2023, subject to customary closing conditions.
  • The offering is being made only by means of a prospectus which is a part of the Registration Statement.

ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

Retrieved on: 
Thursday, September 14, 2023
Insulin, Type 2 diabetes, Obesity, Vagus nerve, SBIR, Weight loss, Pancreas, Vagus nerve stimulation, Diabetes, Electrode, Blood, Alloxan, Hypoglycemia, Animal, Reshaping Cultural Policies, EUS, Bluetooth, Liver, AI, Research, NIH, Pharmaceutical industry, Medical device

Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound (EUS) probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals.

Key Points: 
  • Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound (EUS) probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals.
  • “ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose.
  • Increased glycemic control, has been successfully demonstrated in a Zucker rat model of Type 2 diabetes as well as in an alloxan treated swine model of type 2 diabetes, both of which were completed with the help of an initial NIH grant,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences®.
  • The promise of the DBSN™ device is evidenced, not only by the volume of NIH funding, but also by the presentation of compelling preclinical evidence at multiple medical conferences.

ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023
SAB, Patent, Advertising, DSM-IV codes, Surgeon, Obesity, Type 2 diabetes, Marketing, Adjustable gastric band, Weight loss, Quality of life, Coronavirus Scientific Advisory Board, United States patent law, State Administrative Expenses, Reshaping Cultural Policies, Annual report, SAN, Poster, Growth, Bariatric surgery, Security (finance), Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, T2D, PTE, Food, Pharmaceutical industry, Cryptocurrency, Video game, Diabetes

SAN CLEMENTE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate strategic update.

Key Points: 
  • SAN CLEMENTE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate strategic update.
  • “In 2023, we have continued to leverage operational efficiencies, optimize our lead generation programs, and invest in our growth drivers.
  • During the three months ended March 31, 2023, the company placed more focus on domestic sales, resulting in lower international sales.
  • Gross Profit for both the three months ended March 31, 2023, and 2022, was $1.2 million.

ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering

Retrieved on: 
Wednesday, February 8, 2023
SEC filing, Weight loss, Sale, SAN, Reshaping Cultural Policies, Form, Park Avenue, Prospectus, Exercise, Security (finance)

Each unit was sold at a public offering price of $8.00.

Key Points: 
  • Each unit was sold at a public offering price of $8.00.
  • The warrants in the units are immediately exercisable at a price of $8.00 per share and expire five years from the date of issuance.
  • Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $10.2 million.
  • The offering was made only by means of a prospectus which is a part of the effective registration statement.

ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering

Retrieved on: 
Monday, February 6, 2023
SEC filing, Weight loss, Sale, SAN, Reshaping Cultural Policies, Form, Park Avenue, Prospectus, Exercise, Security (finance)

Each unit is being sold at a public offering price of $8.00.

Key Points: 
  • Each unit is being sold at a public offering price of $8.00.
  • The warrants in the units will be immediately exercisable at a price of $8.00 per share and will expire five years from the date of issuance.
  • Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $10.2 million.
  • The offering is being made only by means of a prospectus which is a part of the effective registration statement.

ReShape Lifesciences Announces $750,000 Registered Direct Offering

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Private Securities Litigation Reform Act, Act, Park Avenue, U.S. Securities and Exchange Commission, Type 2, Proposal, Nasdaq, Telephone, Anatomy, Sale, Form S-3, Stomach, Prospectus, Person, Securities Act of 1933, Regulation D, SEC, Obesity, Ramakanta Panda, Annual report, Form, Collection, Type 2 diabetes, Weight loss, Venture round, Company, Reshaping Cultural Policies, Patient, Security (finance), FDA

Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is expected to be approximately $750,000.

Key Points: 
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is expected to be approximately $750,000.
  • A final prospectus supplement and accompanying prospectus relating to the securities being offered in the registered direct offering will be filed with the SEC.
  • ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease.
  • These forward-looking statements and factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering.

ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®

Retrieved on: 
Thursday, November 3, 2022
Glucose, Private Securities Litigation Reform Act, Diet, Type 2 diabetes, Alloxan, Weight loss, SAN, CA, Obesity, PG, Risk, Industry, GLOBE, Vagotomy, SBIR, Ramakanta Panda, FDA, Safety, Metabolic disorder, Patient, Nasdaq, Plasma, Oxidative stress, Marketing, Roy Taylor (scientist), Research, Vagus nerve, Type 2, Anatomy, Collection, Annual report, U.S. Securities and Exchange Commission, Insulin, Stomach, Pancreas, Diabetes, Forward-looking statement, Reshaping Cultural Policies, CV, Liver, Technology, Security (finance), NIH, Hypoglycemia, SD, Insulin resistance, Ligation, Person, Miniature pig, Pharmaceutical industry, Medical device, T2DM

Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.

Key Points: 
  • Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.
  • Previously, the area under the curve of oral glucose tolerance tests (OGTTs) was calculated to quantify glycemic control.
  • The opportunity to present such compelling data on our proprietary DBSN device at this industry conference is a testament to the market potential of the technology to treat type 2 diabetes, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders.

ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

Retrieved on: 
Monday, October 31, 2022
Consensus, Reshaping Cultural Policies, National, Bariatric surgery, U.S. Securities and Exchange Commission, Leadership, Marketing, BMI, Collection, Obesity, Time, Annual report, Private Securities Litigation Reform Act, SAN, Forward-looking statement, Person, Patient, Society, IFSO, Regulation of tobacco by the U.S. Food and Drug Administration, Type 2, Metabolism, Ramakanta Panda, Adult, Security (finance), Anatomy, GLOBE, Type 2 diabetes, FDA, Weight loss, Population, NIH, FACS, Risk, Nasdaq, Stomach, ASMBS, Pharmaceutical industry, Medical device

SAN CLEMENTE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) have issued updated guidelines for Metabolic and Bariatric Surgery, including the Lap-Band®, replacing the 30 year old guidelines issued by the National Institutes of Health (NIH) in 1991.

Key Points: 
  • The full text of the guidelines can be accessed via the following link https://www.soard.org/article/S1550-7289(22)00641-4/fulltext .
  • Metabolic and bariatric surgery, is currently the most effective evidence-based treatment for obesity across all BMI classes.
  • We applaud the leadership of these two industry-leading societies, working together to update these guidelines for bariatric surgery.
  • ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease.

ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, SBIR, Lists of diseases, Human, Fasting, Reshaping Cultural Policies, Collection, Private Securities Litigation Reform Act, Myocardial infarction, GLOBE, Frontiers, Pancreas, Type 2 diabetes, Plasma, Annual report, Insulin, Marketing, Diabetes, Adjustable gastric band, Miniature pig, Ligation, Disease, Forward-looking statement, Technology, FDA, Patient, Obesity, University, Vagus nerve stimulation, Vagus nerve, Liver, RATS, Nasdaq, Hypoglycemia, Stomach, Research, Anatomy, Risk, Blood, Stroke, Insulin resistance, Ramakanta Panda, Tuskegee Veterans Administration Medical Center, Weight loss, Security (finance), Pharmaceutical industry, Medical device, Alloxan, Neuroscience, Endocrinology, Medicine

SAN CLEMENTE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that data on the Company’s proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system has been published in the Neural Technology Section of the peer reviewed journal Frontiers in NeuroScience.

Key Points: 
  • When this translates to humans and clinical use, it may greatly impact the standard of care for type 2 diabetes.
  • This study specifically tested the ability of the system to increase glycemic control in a rat model of type 2 diabetes and Alloxan treated swine.
  • Based on the data generated, the study concluded that our proprietary DBSN system may be an adjustable and localized approach for treating type 2 diabetes.
  • The DBSN system utilizes a proprietary, reversable and adjustable electrical blockade felt to be key to the future of personalized medicine.

ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)

Retrieved on: 
Thursday, October 20, 2022
Consensus, ASMBS, Long-term care, Decision-making, Weight loss, Reshaping Cultural Policies, Anatomy, Organization, NYU, Society, New York University Grossman School of Medicine, Patient, Lists of diseases, Consensus decision-making, Division, Ramakanta Panda, Aftercare, Collection, Philosophy, Nasdaq, MD, Health, Obesity, Bariatric surgery, Metabolism, GLOBE, Stomach, Literature, FDA, LAGB, Health insurance, Risk management

SAN CLEMENTE, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a Consensus Statement on Lap-Band® use and aftercare management entitled, “American Society of Metabolic and Bariatric Surgery Consensus Statement on Laparoscopic Adjustable Gastric Band Management.”

Key Points: 
  • A formal modified Delphi, 2-stage consensus approach was conducted on Lap-Band management.
  • Consensus Statements were then issued on six domains including behavioral health, nutrition, identification and management of weight loss complications, medical management, special populations and follow-up assessment of Lap-Band patients.
  • ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease.
  • It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.